Table of Contents
What changed
Reported revenue fell 26.4% to $493.6m and PBT fell 43.6% to $27.1m, but NPAT rose 84.2% to $45.2m — a 127.8pp divergence driven by a $30.3m after-tax profit and gain on a discontinued operation (the Community Health segment, previously ~$192.2m of revenue and $5.6m of result, is no longer reported). On continuing operations, management states operating revenue was up 3% to $493m and EBIT down 29% to $34.3m. Pharmacy Services now accounts for ~73% of revenue (up from 54.8%) but its margin compressed to ~5.9% from ~9.8%. Medical Services rose to ~27% of revenue with a ~12.2% margin. Operating cash flow fell 30.3% to $45.9m, yet closing cash rose to $58.2m and gross borrowings eased to $23.5m, leaving net cash of ~$34.7m versus ~$21.1m. A final dividend of 3.5 cps was declared (prior period comparative not disclosed in the extraction).
What matters
- The NPAT headline is not the operating read. Profit from continuing operations was only $20.3m; the $30.3m disposal/discontinued-operation gain does the heavy lifting. PBT, down 43.6%, is the cleaner underlying signal and is further confirmed by EBIT on continuing operations being down 29%.
- Pharmacy Services margin compression. The dominant segment's operating margin roughly halved (~9.8% to ~5.9%) on flat revenue ($367.1m → $360.4m). This is the core earnings-quality issue: the remaining business is more concentrated in a segment where profitability has stepped down materially.
- Balance sheet strengthened despite earnings weakness. Net cash improved by ~$13.6m, equity rose 16.1% to $202.0m, and ROE lifted to 22.4% from 14.1% — but the ROE move is inflated by the same disposal gain that lifted NPAT.
Expectations
No quantified FY24 guidance, forward-work balance, or medium-term target was provided in the supplied materials. On shape, HY23 revenue of $355.1m annualises to ~$710.2m, far above the FY23 $493.6m outcome, reflecting the exit of Community Health rather than a second-half revenue collapse in the retained businesses. NPAT was mechanically second-half-weighted (HY23 NPAT $11.4m vs FY23 $45.2m) only because the disposal gain sits in the second half. The release does not support inference of an underlying H2 run-rate versus any stated target.
Quality of result
Low to mixed. The single largest swing factor — the $30.3m discontinued-operation gain — is non-recurring by definition and should be excluded when assessing run-rate earnings. On the continuing business, PBT fell 43.6% and pre-lease free cash flow declined to ~$40.2m from ~$61.7m, so cash conversion deteriorated materially even before noting that FY23 NPAT is distorted upward. Working capital provided a tailwind: trade debtors fell 55.9% to $13.7m (receivable days ~10 versus ~17), which likely reflects the deconsolidation of the disposed segment rather than operational tightening. The dividend payout of ~11.1% of reported NPAT looks modest, but it would be a higher share of continuing-operation NPAT of $20.3m.
Unresolved
- What were the proceeds, consideration structure, and underlying recurring earnings lost with the Community Health disposal, and how much of FY23 cash/net-cash improvement is disposal-related versus organic?
- What drove Pharmacy Services margin from ~9.8% to ~5.9% — cost inflation, mix, script margin, or one-offs — and is this the new baseline?
- What is the like-for-like continuing-operations prior-period comparison for EBIT/PBT, given the reported numbers mix continuing and discontinued bases?
- Is the 3.5 cps dividend the full-period total or only the final component, and what is the prior-period full-year dividend for comparison?
- No FY24 guidance, no medium-term target, and no customer concentration disclosure were provided.
This briefing cannot assess valuation (no NTA or share-price inputs supplied) or the economic terms of the Community Health exit beyond the disclosed $30.3m after-tax gain.
Key metrics
| Metric | FY23 | FY22 | Change |
|---|---|---|---|
| Revenue | $493.6m | $670.3m | -26.4% ↓ |
| Net profit after tax | $45.2m | $24.6m | +84.2% ↑ |
| Net cash inflow from operating activities | $45.9m | $65.8m | -30.3% ↓ |
| Final dividend per share | 3.5c | — | — |
| Operating profit | $34.3m | $54.1m | -36.6% ↓ |
| Profit before tax | $27.1m | $48.0m | -43.6% ↓ |
| Cash and cash equivalents | $58.2m | $45.2m | +28.9% ↑ |
| Total assets | $401.0m | $408.8m | -1.9% ↓ |
Reference: annolyse.ai/briefings/gxh-fy23
Segment breakdown
| Segment | Current revenue | Prior revenue | Current result | Mix shift |
|---|---|---|---|---|
| Pharmacy Services | $360.4m | $367.1m | $21.1m | +18.2pp |
| Medical Services | $133.2m | $111.0m | $16.2m | +10.4pp |
| Community Health | — | $192.2m | — | n/a |
Reference: annolyse.ai/briefings/gxh-fy23
Analytical metrics
| Metric | FY23 | FY22 | Context |
|---|---|---|---|
| PBT growth | -43.6% | — | cleaner earnings measure |
| Effective tax rate | 25.1% | 29.7% | — |
| FCF pre-lease | $40.2m | $61.7m | −$21.5m |
| FCF / NPAT | 88.9% | 251.4% | complementary conversion metric |
| Capex % revenue | 1.2% | 0.6% | — |
| Capex | $5.7m | −$4.1m | +$9.8m |
| Debtor days | 10.1 | 16.9 | -6.8 days |
| Inventory days | 23.6 | 17.5 | +6.1 days |
| Operating working capital | $45.7m | $63.2m | −$17.6m absorbed |
| Trade debtors | $13.7m | $31.1m | −$17.4m |
| Net debt | −$34.7m | −$21.1m | −$13.6m |
| Gross borrowings | $23.5m | $24.0m | −$0.5m |
| Payout ratio vs NPAT | 11.1% | — | — |
| ROE (annualised) | 22.4% | 14.1% | Strengthening |
| HY23 share of FY23 revenue | 71.9% | — | Other half was 28.1% |
| HY23 share of FY23 NPAT | 25.1% | — | Other half was 74.9% |
| Profit from continuing operations | $20.3m | — | — |
| Discontinued operation after tax | $30.3m | — | — |
Reference: annolyse.ai/briefings/gxh-fy23
This analysis was generated using Annolyse, an AI-powered tool that analyses NZX/ASX company announcements. The analysis is based on available company filings and standard Annolyse calculations. This is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.